Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation

Effect of Perioperative Terlipressin on Postoperative Renal Function in Patients Who Have Undergone Living Donor Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials

“…Table 1 summarizes the details of the included studies. In 1 study, the inclusion criteria were determined by anatomical factors [13], whereas patients in the other studies were included according to clinical conditions (e.g. MELD score, portal hypertension, and the Child-Turcotte-Pugh grade) [14,15].…”

“…Dopamine, norepinephrine, and/or dobutamine was administered to maintain a MAP of >65 mm Hg in the control. In the other studies, the control group received norepinephrine and epinephrine to maintain the hemodynamics; in the terlipressin group, the terlipressin infusion was started at a dose of 3 mg/kg per hour to maintain an MAP of >65 mm Hg, and the dose was reduced to 1.5 mg/ kg per hour after reperfusion, which continued until the third postoperative day [13], or terlipressin was administered as an initial bolus dose of 1 mg over 30 min followed by a continuous infusion of 2 mg/kg per hour for 2 days [15].…”

Updates on hepatorenal syndrome and strategies bridging to liver transplantation

“…[44] In this trial, intraoperative terlipressin infusion significantly decreased hepatic and renal arterial resistive indices, portal venous blood flow and systemic arterial pressure with lower systemic vascular resistance. The need for intraoperative vasoactive support was reduced.…”

Organ protection in allograft recipients

“…Twenty studies reporting on anesthetic strategies aiming at reducing postoperative morbidity and mortality were eventually included (Table 1) [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. We retrieved 14 studies reporting on postoperative complications in patients undergoing liver transplantation [22][23][24]28,29,[31][32][33][35][36][37][39][40][41], five studies conducted in kidney recipients [26,27,30,34,38] and one reporting on lung recipients [25].…”